C12N 2710/16032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2710/16032 (Use of virus as therapeutic agent, other than vaccine) appears on 3 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 7
- Assignees
- 6
- Inventors
- 20
- Latest grant
- 12 Apr 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 2 |
| 2019 | 1 | 1 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer17 Sep 2026US 2026/0273003 A1Virogin Biotech Canada Ltd
- Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors2 Apr 2026US 2026/0091069 A1Virogin Biotech Canada Ltd
- Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells22 Aug 2019US 2019/0255127 A1Batu Biologics, Inc.
- Armed oncolytic viruses21 Jun 2018US 2018/0169241 A1MEMGen Corporation
- Retargeted herpesvirus with a glycoprotein h fusion4 Jan 2018US 2018/0002723 A1Alma Mater Studiorum - Università di Bologna
Most cited
By later US patents